Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study - Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Dolev, Mark; Menascu, Shay; Magalashvili, David; Flechter, Shlomo; Givon, Uri; Guber, Diana; Sonis, Polina; Zilkha-Falb, Rina; et al. (Journal of neuroimmunology, 2021)
Keywords: Adult; Antibodies, Viral - blood; Antirheumatic Agents - therapeutic use; BNT162 Vaccine - immunology; COVID-19; COVID-19 - prevention & control; Cross-Sectional Studies; Disease modifying treatments; Female; Humans; Humoral immunity; IgG antibody; Immunity, Humoral - immunology; Immunoglobulin G - blood; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Prospective Studies; SARS-CoV-2; Vaccination; COVID-19; Multiple sclerosis; IgG antibody; Disease modifying treatments; Vaccination; Humoral immunity